PYXS · Pyxis Oncology, Inc. · Executive Compensation
$1.81
+0.13 (+7.74%)
At close · Nov 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$216.49M
Shares
119.61M
Volume · Nov 20
3.05M
Avg daily vol (3M)
1.06M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | Former President, Chief Executive Officer and Chief Medical Officer | $1,671,545 |
| Pamela Connealy | Former Chief Financial Officer and Chief Operating Officer | $1,425,237 |
| Jitendra Wadhane | Principal Financial and Accounting Officer | $766,752 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | President, Chief Executive Officer and Chief Medical Officer | $7,072,943 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | $2,571,039 |
| Ken Kobayashi | Former Chief Medical Officer | $650,350 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | President, Chief Executive Officer and Chief Medical Officer | $4,442,501 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | $1,821,359 |
| Jay Feingold | M.D., Ph.D. Former Chief Medical Officer | $1,053,444 |
| Ken Kobayashi | Former Chief Medical Officer | $880,013 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | President and Chief Executive Officer | $5,027,073 |
| Jay Feingold | M.D., Ph.D. Former Chief Medical Officer | $2,393,445 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | $2,026,612 |
| Ken Kobayashi | Chief Medical Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | M.D., President and Chief Executive Officer | $17,268,336 |
| Jay Feingold | M.D., Ph.D., Chief Medical Officer | $7,710,098 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | $2,735,364 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | M.D., Chief Executive Officer | $555,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John Flavin | Lead Independent Director | Appointed | 2026-09-08 |
|
Santhosh Palani
“Dr. Palani’s decision to resign was due to increased time commitments associated with his primary professional responsibilities and was not the result of any dispute or disagreement with the Company or the Board.”
|
member of the Company's Board | Resigned | 2026-09-08 |
| Thomas Civik | Chairman of the Board | Appointed | 2026-09-08 |
| Thomas Civik | Chief Executive Officer | Appointed | 2026-09-08 |
|
Pamela Connealy
“Ms. Connealy’s retirement from the Company was not the result of any disagreement with the Company’s independent auditors or any member of management on any matter of accounting principles or practices, financial statement disclosure, or internal controls.”
|
Chief Financial Officer and Chief Operating Officer | Retired | 2025-07-03 |
|
Pamela Connealy
“Ms. Connealy’s retirement from the Company was not the result of any disagreement with the Company’s independent auditors or any member of management on any matter of accounting principles or practices, financial statement disclosure, or internal controls.”
|
Chief Financial Officer and Chief Operating Officer | Retired | 2025-07-03 |
|
Ken Kobayashi, M.D., F.A.C.P
“His resignation will be effective as of March 18, 2025 and is not associated with, or attributable to, any disagreement regarding any matter related to the Company's operations, policies or practices.”
|
Chief Medical Officer | Resigned | 2025-03-18 |
| Michael A. Metzger | Board of Directors | Appointed | 2024-06-10 |
| Santhosh Palani, Ph.D., CFA | Board of Directors | Appointed | 2024-03-13 |
| Ken Kobayashi, M.D., F.A.C.P | Chief Medical Officer | Appointed | 2023-11-28 |
| Jakob Dupont, M.D. | Class III director | Appointed | 2023-08-23 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | Appointed | 2023-03-22 |
| Rachel Humphrey, M.D. | Board of Directors | Appointed | 2022-08-15 |
| Jitendra Wadhane | Chief Accounting Officer and to serve as Principal Accounting Officer | Appointed | 2022-08-09 |
|
Ronald Herbst, Ph.D.
“Neither Mr. Chin’s nor Dr. Herbst’s decision is due to any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices.”
|
Chief Scientific Officer | Resigned | 2022-04-14 |
Leadership
- Thomas Civik CEO, Chairman, Board Member
- Pamela Connealy COO
- Jitendra Wadhane Chief Accounting Officer
- Jakob Dupont, M.D. Board Member
- Michael A. Metzger Board Member
- Rachel Humphrey, M.D. Board Member
- Santhosh Palani, Ph.D., CFA Board Member
Key facts
CIK
1782223
CUSIP
747324101
13F (30d)
107 filings
97 filers
Visit website
Investor relations